NICE guidance (NG28) recommends considering GLP-1 receptor agonists for adults with type 2 diabetes when glycaemic targets are not achieved with other therapies, particularly in those with established cardiovascular disease or at high cardiovascular risk
doi:10.1172/JCI116186 Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA
In terms of weight loss, yes
However, GIPR agonism can potentially decrease the nauseous effects of GLP1 agonism by inhibiting area postrema inhibitory neurons
However, this effect is soon weakened, not affecting the normal heart rate ( Figure 3 Effects on Atherosclerosis Atherosclerosis (AS) is a fibrolipopathic formation on the arterial wall and a main cause of death worldwide
These drugs are clearly pulling levers and pressing buttons in the body that have nothing to do with obesity or insulin